A multi-institutional evaluation of active surveillance for low risk prostate cancer

Journal of Urology

Volumn 189, Issue 1 SUPPL, 2013, Pages

  Eggener, Scott E ^a   Mueller, Alex ^b   Berglund, Ryan K ^b   Ayyathurai, Raj ^c,d   Soloway, Cindy ^c   Soloway, Mark S ^c   Abouassaly, Robert ^d   Klein, Eric A ^d   Jones, Steven J ^d   Zappavigna, Chris ^e   Goldenberg, Larry ^e   Scardino, Peter T ^b   Eastham, James A ^b   Guillonneau, Bertrand ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

biopsy; prostatic neoplasms; treatment outcome

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER RISK; CANCER STAGING; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; THERAPY DELAY;

EID: 84870889258     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.11.023     Document Type: Article

References (20)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray Cancer statistics, 2008 CA Cancer J Clin 58 2008 71
2. M.R. Cooperberg, J.M. Broering, P.W. Kantoff, P.R. Carroll Contemporary trends in low risk prostate cancer: risk assessment and treatment J Urol 178 2007 S14
3. S. Roemeling, M.J. Roobol, M.W. Kattan, T.H. van der Kwast, E.W. Steyerberg, F.H. Schroder Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations Cancer 110 2007 2218
4. C. Warlick, B.J. Trock, P. Landis, J.I. Epstein, H.B. Carter Delayed versus immediate surgical intervention and prostate cancer outcome J Natl Cancer Inst 98 2006 355
5. M.A. Dall'Era, M.R. Cooperberg, J.M. Chan, B.J. Davies, P.C. Albertsen, L.H. Klotz Active surveillance for early-stage prostate cancer: review of the current literature Cancer 112 2008 1650
6. S.E. Eggener, P.T. Scardino, P.R. Carroll, M.J. Zelefsky, O. Sartor, H. Hricak Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities J Urol 178 2007 2260
7. H.B. Carter, A. Kettermann, C. Warlick, E.J. Metter, P. Landis, P.C. Walsh Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience J Urol 178 2007 2359
8. L. Klotz Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer J Urol 172 2004 S48
9. M.I. Patel, D.T. DeConcini, E. Lopez-Corona, M. Ohori, T. Wheeler, P.T. Scardino An analysis of men with clinically localized prostate cancer who deferred definitive therapy J Urol 171 2004 1520
10. M.S. Soloway, C.T. Soloway, S. Williams, R. Ayyathurai, B. Kava, M. Manoharan Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience BJU Int 101 2008 165
11. A.J. Stephenson, P.T. Scardino, J.A. Eastham, F.J. Bianco Jr, Z.A. Dotan, P.A. Fearn Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy J Natl Cancer Inst 98 2006 715
12. C. Hardie, C. Parker, A. Norman, R. Eeles, A. Horwich, R. Huddart Early outcomes of active surveillance for localized prostate cancer BJU Int 95 2005 956
13. D.C. Miller, S.B. Gruber, B.K. Hollenbeck, J.E. Montie, J.T. Wei Incidence of initial local therapy among men with lower-risk prostate cancer in the United States J Natl Cancer Inst 98 2006 1134
14. R.K. Berglund, T.A. Masterson, K.C. Vora, S.E. Eggener, J.A. Eastham, B.D. Guillonneau Pathologic upgrading and upstaging with immediate repeat biopsy for patients eligible for active surveillance J Urol 179 suppl 2008 51 abstract 144
15. T.B. Sheridan, H.B. Carter, W. Wang, P.B. Landis, J.I. Epstein Change in prostate cancer grade over time in men followed expectantly for stage T1c disease J Urol 179 2008 901
16. G. Draisma, R. Boer, S.J. Otto, I.W. van der Cruijsen, R.A. Damhuis, F.H. Schroder Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95 2003 868
17. K. Ito, T. Yamamoto, M. Miyakubo, H. Takechi, M. Ohi, Y. Shibata Lead time of prostate cancer detected in population based screening for prostate cancer in Japan J Urol 178 2007 1258
18. B.R. Konety, V.Y. Bird, S. Deorah, L. Dahmoush Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era J Urol 174 2005 1785
19. N.J. van As, A.R. Norman, K. Thomas, V.S. Khoo, A. Thompson, R.A. Huddart Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance Eur Urol 54 2008 1297
20. J.E. Johansson, O. Andren, S.O. Andersson, P.W. Dickman, L. Holmberg, A. Magnuson Natural history of early, localized prostate cancer JAMA 291 2004 2713